Centrioles: One master to rule them all
Multiciliated cells rely on the same master regulator as dividing cells to amplify the number of centrioles needed to generate the hair-like structures that coat their cell surface.
- Departamento de Bioquímica, Facultad de Medicina, Universidad Autónoma de Madrid, Spain
- Instituto de Investigaciones Biomédicas “Alberto Sols”, Consejo Superior de Investigaciones Científicas, Spain
- CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Spain
The skeleton of filaments that gives animal and other eukaryotic cells their shape is organized in large part by two cylindrical structures called centrioles. Every cell cycle, the centrioles duplicate to form the mitotic spindle that separates the cell’s genetic material evenly between the daughter cells during cell division (Figure 1A). If the centrioles fail to replicate or too many are made, this can lead to diseases like cancer or microcephaly (Nigg and Holland, 2018).
Figure 1
PLK4 is essential for centriole assembly in both cycling cells and differentiating multiciliated cells.
(A) In the first phase of the cell cycle (known as G1), each cell contains two centrioles (grey cylinders): the mother centriole, which is fully mature and contains appendages, and the daughter centriole, which is younger and appendage-free. These centrioles are tethered together and surrounded by an amorphous mass of protein known as the pericentriolar matrix. As cells replicate their DNA (S-phase), each centriole duplicates to form new ‘procentrioles’ via a mechanism regulated by the enzyme PLK4. The procentrioles then elongate into fully formed centrioles. By the G2 phase of the cycle, cells have two pairs of centrioles, which form the mitotic spindle during mitosis (M-phase). The spindle then segregates the centrioles and the cell’s genetic material evenly among the daughter cells. (B) Multiciliated cells (MCCs) arise from progenitor cells that exit their last mitosis with two centrioles, as shown above. During differentiation, these parental centrioles are amplified via two distinct mechanisms: parental centrioles duplicating multiple times to produce new centrioles (top), or centrioles being built from scratch (bottom) using spheroidal, transitory organelles called deuterosomes. Eventually, all the centrioles mature and migrate to the apical surface where they dock to the membrane and form the cell’s cilia. In progenitor cells lacking the enzyme PLK4, neither of these pathways are functional and the cells are unable to differentiate into multiciliated cells.
Image credit: Pablo Barbeito and Francesc R. Garcia-Gonzalo.
Centrioles are also responsible for forming hair-like structures known as cilia, which protrude from the body of certain cells. Some epithelial cells have hundreds of cilia attached to their apical surface, which function like oars in a galley, collectively beating to displace extracellular fluid. These multiciliated cells can be found lining the surface of several organs, including the trachea, reproductive tissues, and the ventricular system in the brain. However, defects in these cells can lead to respiratory infections, infertility, and other cilia-associated disorders (Reiter and Leroux, 2017).
Multiciliated cells arise during development from epithelial progenitor cells that each contain a single centriole pair. To form the hundreds of cilia that will coat the apical surface, the progenitors increase their centriole content either by copying the original pair multiple times, or by building new centrioles in transitory structures called deuterosomes (Figure 1B; Nanjundappa et al., 2019).
During this amplification process (known as A-phase), the levels of an enzyme called PLK4 (short for Polo-like kinase 4) increase, and the enzyme associates with the parental centrioles and deuterosomes (Hoh et al., 2012; Zhao et al., 2013). This protein is the master regulator of centriole assembly and duplication during cell division. However, recent studies found that blocking PLK4 – either with a drug or by silencing its expression – did not prevent multiciliated cells from developing the right number of centrioles and cilia, despite causing a delay in A-phase (Nanjundappa et al., 2019; Mercey et al., 2019a; Mercey et al., 2019b; Zhao et al., 2019; Wong et al., 2015). This led to the conclusion that PLK4 is dispensable for centriole amplification in epithelial progenitors. Now, in eLife, Andrew Holland and co-workers from Johns Hopkins University – including Gina LoMastro as first author – report new results that contradict this theory (LoMastro et al., 2022).
The team created mouse models which contained a modified version of the gene that encodes PLK4: in cells expressing another enzyme called Cre recombinase, the PLK4 gene no longer produced the protein, or only produced an enzymatically inactive form. LoMastro et al. found that epithelial progenitor cells lacking PLK4, or those with a non-functioning version, were unable to amplify their centrioles. Furthermore, the mutant cells could not differentiate into the multiciliated cells in the trachea or the ependymal cells lining the ventricular system in the brain, both in vitro and in vivo.
These findings provide strong evidence that PLK4 and its enzymatic activity are essential for centriole amplification in multiciliated cells. So, why did several high-quality studies appear to show the opposite result? LoMastro et al. found that when the concentration of the drug used in the previous studies was increased (from 1.5 µM to 5–10 µM), it was able to inhibit centriole amplification in ependymal and tracheal multiciliated cells. This suggests that the dose of drug needed to block A-phase is much higher than the amount required to inhibit centriole duplication in cycling cells – which makes sense given that the level of PLK4 is many times higher in A-phase than during the cell cycle (Hoh et al., 2012). Furthermore, LoMastro et al. found that multiciliated cells in the trachea have specialized proteins that pump out the inhibitor, which likely reduced the effectiveness of the drug.
Low drug doses are only part of the story. Previous studies also failed to block A-phase by silencing the expression of the gene for PLK4 using a method called RNAi, even when this was supplemented with the inhibiting drug (Nanjundappa et al., 2019; Zhao et al., 2019). It has since been discovered that the kinetics of building centrioles from scratch are highly dependent on the amount of PLK4 (Nabais et al., 2021), suggesting that cells can tell the difference between having little amounts of the enzyme and none at all. Unlike the Cre recombinase approach used by LoMastro et al., the RNAi technique does not fully eliminate gene expression and cells are likely to still have very low levels of the protein. This small amount of PLK4 may be enough to drive A-phase, which may explain why the epithelial progenitor cells in these prior experiments were still able to amplify their number of centrioles.
The drug may have failed to potentiate the effects of RNAi due to insufficient levels of the inhibitor being administered. Furthermore, this drug is known to increase PLK4 levels by preventing the protein from phosphorylating itself so it can be degraded (Nigg and Holland, 2018). Therefore, if the drug is only partially effective and inhibits some but not all PLK4 molecules, protein levels might still be able to rise, exacerbating the number of PLK4 enzymes that remain unblocked.
Further experiments are needed to investigate these possibilities. Nevertheless, it seems clear that PLK4 is the master of centriole assembly, with multiciliated cells being no exception. Several important questions remain. For instance, much remains unknown about the molecular mechanisms PLK4 activates to drive centriole assembly in cycling and multiciliated cells. In addition, it is poorly understood how the quantity of centrioles is coordinated with the size of the cell’s apical surface. LoMastro et al. found that the apical surface was smaller in PLK4 mutants that were unable to undergo centriole amplification. Since previous studies also found that expanding the apical surface leads to higher centriole numbers, this suggests that both processes are tightly coordinated (Nanjundappa et al., 2019; Kulkarni et al., 2021). Understanding how PLK4 regulates the relationship between cell shape and centriole number will be one of the next frontiers in the field.
References
-
Plk4 triggers autonomous de novo centriole biogenesis and maturationThe Journal of Cell Biology 220:e202008090.https://doi.org/10.1083/jcb.202008090
-
Genes and molecular pathways underpinning ciliopathiesNature Reviews 18:533–547.https://doi.org/10.1038/nrm.2017.60
Article and author information
Author details
Francesc R Garcia-Gonzalo
Publication history
- Version of Record published: September 23, 2022 (version 1)
Copyright
© 2022, Barbeito and Garcia-Gonzalo
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 645
- Page views
-
- 104
- Downloads
-
- 0
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Centrioles: One master to rule them all
eLife 11:e82873.
https://doi.org/10.7554/eLife.82873
Further reading
-
- Cell Biology
- Neuroscience
Mitochondria influence cellular function through both cell-autonomous and non-cell autonomous mechanisms, such as production of paracrine and endocrine factors. Here, we demonstrate that mitochondrial regulation of the secretome is more extensive than previously appreciated, as both genetic and pharmacological disruption of the electron transport chain caused upregulation of the Alzheimer’s disease risk factor apolipoprotein E (APOE) and other secretome components. Indirect disruption of the electron transport chain by gene editing of SLC25A mitochondrial membrane transporters as well as direct genetic and pharmacological disruption of either complexes I, III, or the copper-containing complex IV of the electron transport chain elicited upregulation of APOE transcript, protein, and secretion, up to 49-fold. These APOE phenotypes were robustly expressed in diverse cell types and iPSC-derived human astrocytes as part of an inflammatory gene expression program. Moreover, age- and genotype-dependent decline in brain levels of respiratory complex I preceded an increase in APOE in the 5xFAD mouse model. We propose that mitochondria act as novel upstream regulators of APOE-dependent cellular processes in health and disease.
-
- Cell Biology
Uso1/p115 and RAB1 tether ER-derived vesicles to the Golgi. Uso1/p115 contains a globular-head-domain (GHD), a coiled-coil (CC) mediating dimerization/tethering and a C-terminal region (CTR) interacting with golgins. Uso1/p115 is recruited to vesicles by RAB1. Genetic studies placed Uso1 paradoxically acting upstream of, or in conjunction with RAB1 (Sapperstein et al., 1996). We selected two missense mutations in uso1 resulting in E6K and G540S in the GHD that rescued lethality of rab1-deficient Aspergillus nidulans. The mutations are phenotypically additive, their combination suppressing the complete absence of RAB1, which emphasizes the key physiological role of the GHD. In living hyphae Uso1 recurs on puncta (60 sec half-life) colocalizing partially with the Golgi markers RAB1, Sed5 and GeaA/Gea1/Gea2, and totally with the retrograde cargo receptor Rer1, consistent with Uso1 dwelling in a very early Golgi compartment from which ER residents reaching the Golgi recycled back to the ER. Localization of Uso1, but not of Uso1E6K/G540S, to puncta is abolished by compromising RAB1 function, indicating that E6K/G540S creates interactions bypassing RAB1. That Uso1 delocalization correlates with a decrease in the number of Gea1 cisternae supports that Uso1-and-Rer1-containing puncta are where the protein exerts its physiological role. In S-tag-coprecipitation experiments Uso1 is an associate of the Sed5/Bos1/Bet1/Sec22 SNARE complex zippering vesicles with the Golgi, with Uso1E6K/G540S showing stronger association. Using purified proteins, we show that Bos1 and Bet1 bind the Uso1 GHD directly. However, Bet1 is a strong E6K/G540S-independent binder, whereas Bos1 is weaker but becomes as strong as Bet1 when the GHD carries E6K/G540S. G540S alone markedly increases GHD binding to Bos1, whereas E6K causes a weaker effect, correlating with their phenotypic contributions. AlphaFold2 predicts that G540S increases binding of the GHD to the Bos1 Habc domain. In contrast, E6K lies in an N-terminal, potentially alpha-helical, region that sensitive genetic tests indicate as required for full Uso1 function. Remarkably, this region is at the end of the GHD basket opposite to the end predicted to interact with Bos1. We show that unlike dimeric full-length and CTR∆ Uso1 proteins, the GHD lacking the CC/CTR dimerization domain, whether originating from bacteria or Aspergillus extracts and irrespective of whether it carries or not E6K/G540S, would appear to be monomeric. With the finding that overexpression of E6K/G540S and wild-type GHD complement uso1∆, our data indicate that the GHD monomer is capable of providing, at least partially, the essential Uso1 functions, and that long-range tethering activity is dispensable. Rather, these findings strongly suggest that the essential role of Uso1 involves the regulation of SNAREs.
